CN106728143A - Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof - Google Patents

Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof Download PDF

Info

Publication number
CN106728143A
CN106728143A CN201611133198.6A CN201611133198A CN106728143A CN 106728143 A CN106728143 A CN 106728143A CN 201611133198 A CN201611133198 A CN 201611133198A CN 106728143 A CN106728143 A CN 106728143A
Authority
CN
China
Prior art keywords
ethanol
weight
pharmaceutical composition
weight portion
percent concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133198.6A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133198.6A priority Critical patent/CN106728143A/en
Publication of CN106728143A publication Critical patent/CN106728143A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof, pharmaceutical composition of the present invention is with liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, preventing and treating vitreous opacity is evident in efficacy.

Description

Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating vitreous opacity and its preparation Method.
Background technology
Vitreous opacity (vitreous opacities) is not name of disease but a kind of most common phenomenon of vitreum.It is various Eye illness can cause vitreous opacity, and most commonly senile degeneration, Myopia change, posterior detachment of vitreous and physiological flies Mosquito disease, detachment of retina, uveitis, primary familial amyloidosis, synchysis scintillans etc. can also go out in addition The clinical manifestations such as existing muscae genetic vision.Vitreum is transparent gelatinous tissue, is clearly become clear, and it can make vitreous gel performance steady It is fixed, ensure that vitreum and its retina of surrounding are buffered in Rotation of eyeball or when being shaken.And clearly have no time in the visual field, protect The acuity of eyesight is demonstrate,proved.If occurring in that the opaque body in addition to normal configuration, referred to as vitreous opacity in vitreum. Its main clinic symptoms has:Morbidity is unexpected, often has repeatedly.Occur column of smoke formula or black clouds shape shadow at the moment, the blindness quickly having, only Stay light sensation.Main physical signs are:See in vitreum there is cerise clot under slit-lamp, or the outmoded bleeding of brown color.See under ophthalmoscope Dirt shape, strip and block muddiness are floated, or rarely seen dilute micro- feux rouges, or without feux rouges.Repeated Hemorrhage person, visible proliferative in vitreum Bar rope or film, with new vessels.Corticosteroid hormone, hemostasis, anti-freezing, enzyme preparation, Operand, calcium are used modern medicine more Agent, ultrasonic wave, sodium iodide current iontophoresis, laser and vitrectomy etc. are treated, but can not use ultrasound to fresh focus Ripple, laser and operation etc. are treated；Especially patient with slight symptoms is reluctant to be treated surgically most of patient, therefore necessary searching New effective treatment method.
Common anotis herb：It is Rubiaceae vacation plants of Hedyotis common anotis herb Anotis ingrata (wall.) Hook. F. The herb of [Neanotis yngrata (Wall.ex Hook .f) W.H.Lewis].Summer, autumn receive adopt herb, eliminate soil, Debris, dry standby.【Nature and flavor】Taste is pungent；It is cool in nature.【Return through】The heart；Liver Channel.【Indication】Clearing liver-fire.Main nameless sores or boils；Mesh It is crimson swollen；Venomous snake bite.【Former phytomorph】Renascent herb, up to 1m.Stem branch or does not have a small number of branches, it is upright or under The sleeping ground in portion.Leaf opposite；Petiole is short；The nearly triangle in stipule bottom, joint is born between two petioles, edge tool fine hair；Blade Papery, oval or oval long are to ovum shape lanceolar, and 4-9cm long, about 1.8cm wide, tip is tapering, base portion wedge shape, full edge, Two sides is by pubescence.Dichasium basidixed, total bennet and branch have narrow aliform corner angle；Floral white, without obstructing or have short Stalk；Calyx 4 splits, sliver triangular shape lanceolar, and corolla is about 5mm, and hat manages slightly wider, interior raw pubescence；Stamen 4, flower pesticide exposes corolla Outward；Ovary is the next, and Room 2, column cap 2 splits.Capsule is subsphaeroidal, slightly flat-sided, about 2mm wide.Seed is small and most, plano-convex, there is small wart point. The month at florescence 6-7, the fruiting period 7-8 months.Record in dictionary of medicinal plant.
Liana cuneate lespedeza herb with root：It is Convolvulaceae white crane Calamus plant gray wool white crane rattan Argyreia osyrensis (Roth) The leaf of Choisy var.cinerea Hand.-Mazz. [lettsomia bella auct. Non C. B.Clarke] or Root.Ye Xia, autumn harvesting, dry；Root whole year can adopt, clean, section, dry.【Nature and flavor】It is puckery；Temperature.【Indication】Inducing astrigency is consolidated It is de-；Astringe the lung；Hemostasis.Main rush down prolapse of the anus for a long time；The prolapse of uterus；Deficiency syndrome of the lung cough and asthma；Menorrhalgia；Traumatism and bleeding.【Proterties】The many shrinkages of leaf are broken It is broken.It is in avette or wealthy avette, 6-12cm long, 3.5-11cm wide after complete leaf flattening, the sharp point of tip, base portion is heart-shaped, and upper surface is close By the pubescence grey long of tool warty base portion, the grey pubescence that lower surface is curled；Petiole 3-3.5cm long, close that pubescence is crimped by grey, tool Groove, gas is micro-, mildly bitter flavor.【Former phytomorph】Gray wool white crane rattan climbing shrub.Stem cylinder, it is close by white or with grey or light Brown fine hair.Single leaf alternate；Petiole 3-7.5cm long, it is close that pubescence is crimped by grey, have groove；Blade width egg shape to subcircular, 6- long 12cm, 3.5-11cm wide, the sharp point of tip, base portion are heart-shaped, above the close grey pubescence long of lying prostrate for being had a warty base portion, the back side is close by pole It is close and crimp grey pubescence.Inflorescence is gathered into head, flower stockless or nearly stockless；Total bennet, bract and sepal outside are by fine hair； Corolla tubulose is bell, pink, and limb deep 5 splits, and sliver is narrow avette, with close by white pubescence in valve；Stamen and style stretch out；Flower Silk base portion expands, by hair；Ovary without hair, Room 2.It is really spherical, it is red, the sepal to increase is wrapped, sepal inner face is red.2, seed Or 1, it is bordering on without hair.Autumn at florescence, winter.Record in dictionary of medicinal plant.
Herba Cynanchum decipies Schneid：This product is the root of Asclepiadaceae Cynanchum glaucescens platymiscium Herba Cynanchum decipies Schneid Cynanchum decipiens Schneid.. Summer, autumn with adopt with.【Toxicity】There is inhibitory action to pyococcus and various dermatophytes.【Nature and flavor】It is poisonous.【Return through】 Liver Channel.【Indication】Wind-dispelling；Desinsection；It is antipruritic.Main mange.【Pharmacological action】Anticonvulsant action；Calm, analgesic activity；Toxicity： Major toxicity show as it is first slight suppress, spontaneous activity is reduced, then instability of gait, rocks and develop into clonic convulsion and strong Straightforward convulsions, sustainable more than 10 hours of convulsions recurrent exerbation, people's status convulsivus of going forward side by side and it is dead.There is animal during convulsive attack Shout, largely salivate etc..Record in dictionary of medicinal plant.
Herba Chelonopsis chekiangensis：This product is Labiatae Chelonopsis plant Herba Chelonopsis chekiangensis Chelonopsis The root or herb of chekiangensis C. Y. Wu.Root, autumn harvesting, cleans, using fresh herb；Cauline leaf, summer harvesting, dries.【Property Taste】Taste is pungent；It is warm in nature.【Indication】Dispersing wind and cold；Degrading the channel；Disperse accumulations.Main anemofrigid cold；Cough；Muscles and bones is ached；Dyspeptic abdominal distention. 【Former phytomorph】Herba Chelonopsis chekiangensis, herbaceos perennial, about 60cm high.Tool rhizome；Stem is upright, four prismatics, and how many tools are hard Hair.Leaf opposite；Petiole 0.4-3cm long；Blade lanceolar, 3-15cm long, 1.5-4.5cm wide, tip is tapering, and base portion wedge shape is gradually narrow Into long handle, above have the thin calm hair that tool saves on the arteries and veins of face, remainder sparsely grow bristle, below the sparsely grow thin calm hair of tool section on arteries and veins, Arcuation net knot is significant, and Stockwork veinlet is sparse, and edge has sharp shallow sawtooth.The discrimination of cyme two, axillary, tool 3-5 flowers；Squamella 2, drapes over one's shoulders Aciculiform is more long than bennet；Calyx mitriform, 8-10mm long spends rear cryptomere to increase, up to 2cm, the big and blunt triangle such as or not tool 4-5 Shape tooth, the outside sparsely grow tool calm hair of section, becomes without hair afterwards；Corolla two brings disgrace to shape, and light violet color, 3-4cm long, upper lip full edge, lower lip 3 splits, In split toward larger；Stamen 4, preceding to more long, filigree has micro- pubescence, and the Room of flower pesticide 2 is substantially diverged, front tool whisker；Ovary 4 is split, post First 2 shallow split.Pyrene Long Circle, tool is about the wing of 1cm.Florescence August, the fruiting period 9-10 months.Record in dictionary of medicinal plant.
Pale reddish brown trachelospermum jasminoide：This product is the pale reddish brown trachelospermum jasminoide Trachelospermum axillare of Apocynaceae trachelospermum jasminoide platymiscium Hook.f. stem rattan and stem skin.Summer, autumn harvesting, are cleaned, and segment is dried.【Nature and flavor】It is pungent；Slight bitter；It is warm in nature；It is poisonous.【Return through】 Lung；Liver Channel.【Indication】Expel pathogenic wind from the body surface；Active pain relieving.Main cold headache；Cough；Arthralgia pain due to rheumatism；Traumatic injury.【Proterties】 Stem rattan cylinder, outer surface taupe, hole skin transverse projections, and have the band of micro-protuberance；Matter is hard, and skin zone has sparse when fractureing White collodion silk, it is nonelastic.Gas is micro-, mildly bitter flavor.Stem skin drum or channel-shaped, outer surface taupe, inner surface yellow-white or yellowish-brown Color, has thin longitudinal crack.There is sparse white collodion silk when fractureing.Record in dictionary of medicinal plant.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of drug regimen of effective preventing and treating vitreous opacity Thing and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition of the preventing and treating vitreous opacity be：
The liana cuneate lespedeza herb with root 306-310 pale reddish brown trachelospermum jasminoide 10-14 weight portion common anotis herbs of weight portion Herba Cynanchum decipies Schneid 282-288 weight portions 162-164 weight portion Herba Chelonopsis chekiangensis 60-62 weight portions.
The pharmaceutical composition of preventing and treating vitreous opacity is preferably used in, is made up of the bulk drug of following weight portion：
The pale reddish brown weight portion Zhejiang of 12 weight portion common anotis herb of trachelospermum jasminoide 163 of the weight portion of 308 weight portion Herba Cynanchum decipies Schneid of liana cuneate lespedeza herb with root 285 Fragrant 61 weight portion of bell.
A kind of pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition can be using the normal of galenic pharmacy Rule method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition is constituted with chemical drugs or Chinese medicine Preventing and treating vitreous opacity medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The liana cuneate lespedeza herb with root 306-310 weight portion Herba Cynanchum decipies Schneid pale reddish brown networks of 282-288 weight portions Stone 10-14 weight portion common anotis herb 162-164 weight portion Herba Chelonopsis chekiangensis 60-62 weight portions；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
The preparation method of preferred a kind of pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that make as follows It is standby：
The composition and weight portion of bulk drug be：The pale reddish brown weight of trachelospermum jasminoide 12 of the weight portion of 308 weight portion Herba Cynanchum decipies Schneid of liana cuneate lespedeza herb with root 285 The weight portion of 163 weight portion Herba Chelonopsis chekiangensis of part common anotis herb 61；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition can be used The conventional method of galenic pharmacy prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition and chemical drugs Or Chinese medicine composition preventing and treating vitreous opacity medicine.
Pharmaceutical composition preventing and treating vitreous opacity is evident in efficacy.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Liana cuneate lespedeza herb with root 308g Herba Cynanchum decipies Schneids The pale reddish brown trachelospermum jasminoide 12g common anotis herbs 163g Herba Chelonopsis chekiangensis 61g of 285g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Liana cuneate lespedeza herb with root 306g Herba Cynanchum decipies Schneids The pale reddish brown trachelospermum jasminoide 10g common anotis herbs 164g Herba Chelonopsis chekiangensis 60g of 288g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Liana cuneate lespedeza herb with root 310g Herba Cynanchum decipies Schneids The pale reddish brown trachelospermum jasminoide 14g common anotis herbs 162g Herba Chelonopsis chekiangensis 62g of 282g；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 188g of Example 1, adds starch 170g, mixes, and granulation is dried, plus microcrystalline cellulose 65g, stearic Sour magnesium 5g, mixes, and is pressed into 900, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 408g of Example 2, adds starch 290g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 1300, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 180g water-baths and boil molten, add the pharmaceutical composition 13g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.6cm away from liquid level, and drop speed is optimum condition with every point 56 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：Prevent and treat the pharmaceutical composition of vitreous opacity
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 8 weight portion common anotis herb of pale reddish brown trachelospermum jasminoide, 180 weight portion Herba Cynanchum decipies Schneid 290.
Embodiment 8：Prevent and treat the pharmaceutical composition of vitreous opacity
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 12 weight portion common anotis herb of pale reddish brown trachelospermum jasminoide, 150 weight portion Herba Chelonopsis chekiangensis 60.
Embodiment 9：Prevent and treat the pharmaceutical composition of vitreous opacity
Prevent and treat vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 3.5 weight portion common anotis herb of pale reddish brown trachelospermum jasminoide, 140 weight portion Herba Chelonopsis chekiangensis 70.
Experimental example 1：Prevent and treat the experimental study of vitreous opacity
1 data and method
1.1 case-datas
City's hospital outpatient and inpatient department amount to 40 60 vitreums and mix during in the July, 2012 in April, 2013 altogether Turbid patient, wherein man 20, female 20, age 20-73 Sui.Simple eye 20, eyes 20, the cause of disease that vitreous opacity occurs: Moderate and high myopia；Traumatic hematocele, diabetic keratopathy bleeding, Retinopathy of Hypertension.All patients meet following standard: （1）Feel there is shadow at the moment, shape differs, dense or light, erratic motion during Rotation of eyeball.（2）The lighter does not affect one's power of vision, weight Person affects one's power of vision.（3）Eyeground transillumination is checked:When making the tested eye of patient rotate up and down, it is seen that black or have it is translucent it Point-like, strip, block muddiness are waved.（4）Slit-lamp adds its position of preset lens observable and proterties.（5）Make eye ultrasound if necessary Check and visual electrophsiology inspection, understand the property and retina situation of vitreous opacity.It is divided into two groups by random digits table, its Middle treatment group 20 30, control group 20 30.Situations such as two groups of patient ages, sex, state of an illness are distributed is compared to without significantly Sex differernce, with comparativity.
1.2 treatment methods
Two groups take the cause of disease, suit the medicine to the illness, supporting treatment:If any traumatic vitreous hemorrhage person, give and stop blooding, promote blood absorption Deng treatment；If any intraocular inflammation person, anti-inflammatory treatment is given；Cure the Primary Disease.Other treatment group:Combination of oral medication (pharmaceutical composition of embodiment 1), 2g/ times, 2 times a day.Control group:Oral Qiju Dihuang Wan (production of Beijing Tongrentang), 9g/ Secondary, 2 times a day.Two groups are continuously treated 3 months, further consultation every month 1 time, and to follow-up of patients to 6th month.
1.3 the standard of curative effect evaluation
Observation index:Treatment before and treatment 3 months after row slit-lamp, ophthalmoscope and eye test respectively, observe Different therapeutical effect, lead to Cross ultrasonic examination vitreous opacity absorbing state.Vitreous opacity presses standard level Four point-score:1 grade:Vitreous opacity but do not influence Fundus observation；2 grades:Eyeground reflection to red light substantially, dim can be got a glimpse of regarding nipple and blood vessel；3 grades:There is reflection to red light on eyeground, sees not See optical fundus blood vessel；4 grades:Lesser ring of Merkel has reflection to red light.Curative effect determinate standard:Efficacy evaluation is with reference to directly funduscopy after mydriasis Result and eye test result.It is effective:Vitreous opacity is substantially absorbed, and primary affection has been controlled, and symptom disappears, and eyesight improves 5 More than row, vitreous opacity is high-visible to eyeground by 2 level restorations by 3 grades to 1 grade by 4 grades to 2 grades；Effectively:Vitreum is mixed It is turbid to partially absorb, symptom mitigation, eyesight improve 2-5 rows, vitreous opacity by 4 grades to 3 grades, by 3 grades to 2 grades；It is invalid:Vitreum Muddy unchanged or exacerbation, without improvement, eyesight is without improve for symptom.Body temperature, breathing, arteries and veins are surveyed before and after other each patient's treatment Fight, the general indicator such as blood pressure, and blood, urine, feces routine test, security is evaluated in Liver and kidney function and Electrocardioscopy.
1.4 statistical methods
Analyzed using EPITABLE statistical softwares.Enumeration data uses Chi-square Test, P<0.05 indicates significant difference.
2 results
2.1 comparitive studies
The results are shown in Table 1.
The treatment results of each group of table 1
Group N (eye) It is effective Effectively It is invalid Obvious effective rate (%) Total effective rate (%)
Treatment group 30 16 13 1 53.33* 96.67*
Control group 30 11 11 8 36.67 73.33
*:P<0.05, compared with control group, there is significant difference.
2. 2 adverse reactions are compared
Before and after treatment group and control group treatment there is no obvious ANOMALOUS VARIATIONS in safety indexes.

Claims (8)

1. it is a kind of prevent and treat vitreous opacity pharmaceutical composition, it is characterised in that be made the composition of the bulk drug of the pharmaceutical composition It is with weight portion：
The liana cuneate lespedeza herb with root 306-310 pale reddish brown trachelospermum jasminoide 10-14 weight portion common anotis herbs of weight portion Herba Cynanchum decipies Schneid 282-288 weight portions 162-164 weight portion Herba Chelonopsis chekiangensis 60-62 weight portions.
2. according to claim 1 it is a kind of prevent and treat vitreous opacity pharmaceutical composition, it is characterised in that be made the medicine group The composition and weight portion of the bulk drug of compound be：
The pale reddish brown weight portion Zhejiang of 12 weight portion common anotis herb of trachelospermum jasminoide 163 of the weight portion of 308 weight portion Herba Cynanchum decipies Schneid of liana cuneate lespedeza herb with root 285 Fragrant 61 weight portion of bell.
3. according to claim 1 it is a kind of prevent and treat vitreous opacity pharmaceutical composition, it is characterised in that pharmaceutical composition can Piece agent or capsule or dripping pill are prepared with using the conventional method of galenic pharmacy.
4. according to claim 1 it is a kind of prevent and treat vitreous opacity pharmaceutical composition, it is characterised in that pharmaceutical composition with The preventing and treating vitreous opacity medicine of chemical drugs or Chinese medicine composition.
5. it is a kind of prevent and treat vitreous opacity pharmaceutical composition preparation method, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The liana cuneate lespedeza herb with root 306-310 weight portion Herba Cynanchum decipies Schneid pale reddish brown networks of 282-288 weight portions Stone 10-14 weight portion common anotis herb 162-164 weight portion Herba Chelonopsis chekiangensis 60-62 weight portions；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. according to claim 5 it is a kind of prevent and treat vitreous opacity pharmaceutical composition preparation method, it is characterised in that press It is prepared by following steps：
The composition and weight portion of bulk drug be：The pale reddish brown weight of trachelospermum jasminoide 12 of the weight portion of 308 weight portion Herba Cynanchum decipies Schneid of liana cuneate lespedeza herb with root 285 The weight portion of 163 weight portion Herba Chelonopsis chekiangensis of part common anotis herb 61；
Preparation method：
（1）Liana cuneate lespedeza herb with root, Herba Cynanchum decipies Schneid, pale reddish brown trachelospermum jasminoide, common anotis herb, Herba Chelonopsis chekiangensis are taken by bulk drug proportioning, is mixed, use weight The ethanol of percent concentration 39% takes as solvent in 27 DEG C of temperature extractions, and extraction time is 2 times, and each extraction time is 37 hours, Each solvent load is 75 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, is concentrated into Relative density 1.07, filtration, liquid is first washed with water, then use weight percent concentration by LK002 large pore resin absorption columns 23% ethanol solution elutes LK002 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 23%, reclaims ethanol, Concentrate drying, obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 62% as solvent, heating and refluxing extraction 15 times is carried every time The time is taken for 0.1 hour, each solvent load is 47 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.09 is concentrated into, filtered, liquid is first washed with water, then use by SIP1200 large pore resin absorption columns The ethanol solution of weight percent concentration 85% elutes SIP1200 large pore resin absorption columns, collects the ethanol of weight percent concentration 85% Eluent, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. according to claim 5 it is a kind of prevent and treat vitreous opacity pharmaceutical composition preparation method, it is characterised in that medicine Compositions can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. according to claim 5 it is a kind of prevent and treat vitreous opacity pharmaceutical composition preparation method, it is characterised in that medicine Compositions and chemical drugs or Chinese medicine composition preventing and treating vitreous opacity medicine.
CN201611133198.6A 2016-12-10 2016-12-10 Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof Withdrawn CN106728143A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133198.6A CN106728143A (en) 2016-12-10 2016-12-10 Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133198.6A CN106728143A (en) 2016-12-10 2016-12-10 Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106728143A true CN106728143A (en) 2017-05-31

Family

ID=58875014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133198.6A Withdrawn CN106728143A (en) 2016-12-10 2016-12-10 Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106728143A (en)

Similar Documents

Publication Publication Date Title
CN109512870B (en) Pharmaceutical composition, preparation method and application thereof
CN106728143A (en) Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
CN103251725B (en) A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared
CN101129797B (en) Medicine for treating closure type exogenous injury and internal damage and method of producing the same
CN104096153A (en) Pharmaceutical composition containing multiple plant active ingredients and preparation method and application thereof
CN106668240A (en) Pharmaceutical composition for treating vitreous opacity
CN106581221A (en) Pharmaceutical composition for treating vitreous opacity
CN106620269A (en) Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof
CN106619816A (en) Pharmaceutical composition for treating optic atrophy
CN106581122A (en) Pharmaceutical composition for treating acute cervicitis
CN106727854A (en) A kind of pharmaceutical composition for treating synovitis
CN106539929A (en) It is a kind of to treat pharmaceutical composition of vitreous opacity and preparation method thereof
CN104189365B (en) Treat the Chinese medicine composition and its preparation and preparation method of human body pain
CN106511545A (en) Medicinal composition for treating vitreous opacity
CN106728893A (en) Treat pharmaceutical composition of diabetic retinopathy and preparation method thereof
CN106581220A (en) Pharmaceutical composition for preventing and treating vitreous opacity
CN106581222A (en) Pharmaceutical composition for treating suspension of vitreous body
CN106692576A (en) Medicinal composition for treating glaucoma
CN106619754A (en) Medicine compound for treating glaucoma
CN106728422A (en) It is a kind of to prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
CN106668239A (en) Pharmaceutical composition for preventing vitreous opacity
CN106727851A (en) Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106728894A (en) A kind of pharmaceutical composition for preventing and treating keratitis
CN106668395A (en) Pharmaceutical composition for preventing and treating glaucoma
CN106540090A (en) Prevent and treat pharmaceutical composition of optic atrophy and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531